# Ra Capital Management, L.P. 13F Q2 2026: $11.5 billion

Ra Capital Management, L.P. reported $11.5 billion in 13F securities across 84 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Ascendis Pharma A/S at $2.7 billion, 23.8% of the reported value. Since Q1 2026 it opened 17 new positions and exited 18.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $11,507,522,068
- Positions: 84
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1346824
- Form 13F file number: 028-12884
- Business address: 200 Berkeley Street, 18th Floor, Boston, MA 02116
- SEC filing: [0001104659-26-097251](https://www.sec.gov/Archives/edgar/data/1346824/000110465926097251/0001104659-26-097251-index.htm)

## Top 25 holdings by value

The largest of 84 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 10,281,496 | $2.74 billion | New |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 28,933,371 | $791.9 million | New |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 6,666,837 | $740.2 million | No change |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 11,474,599 | $667 million | No change |
| [Sionna Therapeutics Inc](https://specstream.ai/data/institutional-holders/sionna-therapeutics-inc-829401108) | COM | 9,905,045 | $435.7 million | No change |
| [Tyra Biosciences Inc](https://specstream.ai/data/institutional-holders/tyra-biosciences-inc-90240b106) | COM | 12,198,625 | $389.6 million | No change |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 8,392,730 | $341 million | -2,035,707 |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 9,550,191 | $323.7 million | No change |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 7,808,627 | $286.8 million | New |
| [Septerna Inc](https://specstream.ai/data/institutional-holders/septerna-inc-81734d104) | COM | 6,995,858 | $234.3 million | No change |
| [Bicara Therapeutics Inc](https://specstream.ai/data/institutional-holders/bicara-therapeutics-inc-055477103) | COM | 7,255,993 | $215.4 million | No change |
| [Mineralys Therapeutics Inc](https://specstream.ai/data/institutional-holders/mineralys-therapeutics-inc-603170101) | COM | 7,692,750 | $207.6 million | No change |
| [GH Research PLC](https://specstream.ai/data/institutional-holders/gh-research-plc-g3855l106) | ORDINARY SHARES | 7,636,813 | $205.3 million | -39,884 |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 2,450,221 | $179.2 million | No change |
| [Spyglass Pharma Inc](https://specstream.ai/data/institutional-holders/spyglass-pharma-inc-85220g109) | COM SHS | 8,021,117 | $178.6 million | No change |
| [Artiva Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/artiva-biotherapeutics-inc-04317a107) | COM | 17,955,642 | $174.2 million | +8,102,340 |
| [Janux Therapeutics Inc](https://specstream.ai/data/institutional-holders/janux-therapeutics-inc-47103j105) | COM | 11,189,693 | $171.9 million | No change |
| [Taysha Gene Therapies Inc](https://specstream.ai/data/institutional-holders/taysha-gene-therapies-inc-877619106) | COM SHS | 23,555,648 | $160.4 million | No change |
| [Biocryst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/biocryst-pharmaceuticals-inc-09058v103) | COM | 15,827,186 | $158.3 million | No change |
| [Wave Life Sciences LTD](https://specstream.ai/data/institutional-holders/wave-life-sciences-ltd-y95308105) | SHS | 26,975,505 | $156.7 million | No change |
| [Nuvalent Inc](https://specstream.ai/data/institutional-holders/nuvalent-inc-670703107) | COM | 1,246,456 | $153.9 million | -1,287,689 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 1,132,557 | $150.9 million | New |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 1,554,597 | $148 million | New |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 11,300,939 | $147.4 million | No change |
| [Solid Biosciences Inc](https://specstream.ai/data/institutional-holders/solid-biosciences-inc-83422e204) | COM NEW | 12,036,126 | $120.2 million | +2,696,148 |

## New positions in Q2 2026

17 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 10,281,496 | $2.74 billion |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 28,933,371 | $791.9 million |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 7,808,627 | $286.8 million |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 1,132,557 | $150.9 million |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 1,554,597 | $148 million |
| [Intellia Therapeutics Inc](https://specstream.ai/data/institutional-holders/intellia-therapeutics-inc-45826j105) | COM | 4,526,926 | $76.6 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 1,500,000 | $70.6 million |
| [Sana Biotechnology Inc](https://specstream.ai/data/institutional-holders/sana-biotechnology-inc-799566104) | COM | 18,750,000 | $65.4 million |
| [Prelude Therapeutics Inc](https://specstream.ai/data/institutional-holders/prelude-therapeutics-inc-74065p101) | COM | 6,475,882 | $34.5 million |
| [Q32 Bio Inc](https://specstream.ai/data/institutional-holders/q32-bio-inc-746964105) | COM | 2,332,457 | $29.7 million |
| [Editas Medicine Inc](https://specstream.ai/data/institutional-holders/editas-medicine-inc-28106w103) | COM | 8,889,000 | $28.8 million |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 6,500,000 | $19.8 million |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 722,020 | $18.1 million |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 2,500,000 | $17.8 million |
| [Seaport Therapeutics Inc](https://specstream.ai/data/institutional-holders/seaport-therapeutics-inc-81221k108) | COMMON STOCK | 700,000 | $15.2 million |
| [Jatt II Acquisition Corp](https://specstream.ai/data/institutional-holders/jatt-ii-acquisition-corp-g50765109) | ORD SHS | 500,000 | $5.7 million |
| [Amanat Acquisition Corp](https://specstream.ai/data/institutional-holders/amanat-acquisition-corp-g0375m101) | CL A ORD | 375,000 | $3.8 million |

## Positions exited in Q2 2026

18 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Ascendis Pharma A/S | SPONSORED ADR | 10,281,496 | $2.35 billion |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 2,611,733 | $219.2 million |
| [Praxis Precision Medicines I](https://specstream.ai/data/institutional-holders/praxis-precision-medicines-i-74006w207) | COM NEW | 373,787 | $120.4 million |
| [Sarepta Therapeutics Inc](https://specstream.ai/data/institutional-holders/sarepta-therapeutics-inc-803607100) | COM | 3,902,596 | $84.9 million |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 1,621,620 | $81.8 million |
| [Fulcrum Therapeutics Inc](https://specstream.ai/data/institutional-holders/fulcrum-therapeutics-inc-359616109) | COM | 6,053,960 | $46.4 million |
| [Olema Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/olema-pharmaceuticals-inc-68062p106) | COM | 2,600,000 | $38.8 million |
| [Design Therapeutics Inc](https://specstream.ai/data/institutional-holders/design-therapeutics-inc-25056l103) | COM | 2,972,973 | $31.6 million |
| [Travere Therapeutics Inc](https://specstream.ai/data/institutional-holders/travere-therapeutics-inc-89422g107) | COM | 746,841 | $22.2 million |
| [Grail Inc](https://specstream.ai/data/institutional-holders/grail-inc-384747101) | COM | 428,266 | $22.1 million |
| [Relmada Therapeutics Inc](https://specstream.ai/data/institutional-holders/relmada-therapeutics-inc-75955j402) | COM | 2,947,369 | $20.5 million |
| [Sutro Biopharma Inc](https://specstream.ai/data/institutional-holders/sutro-biopharma-inc-869367201) | COM SHS | 715,307 | $17.8 million |
| [Contineum Therapeutics Inc](https://specstream.ai/data/institutional-holders/contineum-therapeutics-inc-21217b100) | CL A | 1,296,012 | $16.9 million |
| [Inspire Med Sys Inc](https://specstream.ai/data/institutional-holders/inspire-med-sys-inc-457730109) | COM | 325,663 | $16.8 million |
| [Hinge Health Inc](https://specstream.ai/data/institutional-holders/hinge-health-inc-433313103) | CL A | 364,613 | $14.1 million |
| [Genedx Holdings Corp](https://specstream.ai/data/institutional-holders/genedx-holdings-corp-81663l200) | COM CL A | 209,887 | $13.5 million |
| [Atrium Therapeutics Inc](https://specstream.ai/data/institutional-holders/atrium-therapeutics-inc-04965n104) | COM | 864,102 | $11.6 million |
| [Maplight Therapeutics Inc](https://specstream.ai/data/institutional-holders/maplight-therapeutics-inc-56565p103) | COM | 248,294 | $5 million |

## Also on SpecStream

- [Ra Capital Management, L.P. Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1346824/000110465926097251/0001104659-26-097251-index.htm)
- [Largest 13F filers in Massachusetts](https://specstream.ai/data/institutional-holdings/state/massachusetts)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Boston, Massachusetts

- [Marketing agencies in Boston, Massachusetts](https://specstream.ai/data/businesses/marketing-agencies/boston-massachusetts-united-states)
- [American restaurants in Boston, Massachusetts](https://specstream.ai/data/businesses/american-restaurants/boston-massachusetts-united-states)
- [Graphic design firms in Boston, Massachusetts](https://specstream.ai/data/businesses/graphic-design-firms/boston-massachusetts-united-states)
- [Publishers in Boston, Massachusetts](https://specstream.ai/data/businesses/publishers/boston-massachusetts-united-states)
- [Construction companies in Boston, Massachusetts](https://specstream.ai/data/businesses/construction-companies/boston-massachusetts-united-states)
- [Mental health clinics in Boston, Massachusetts](https://specstream.ai/data/businesses/mental-health-clinics/boston-massachusetts-united-states)
